Intermittent chemotherapy in metastatic androgen-independent prostate cancer

British Journal of Cancer

Volumn 89, Issue 6, 2003, Pages 968-970

  Beer, T M ^a   Garzotto, M ^b   Henner, W D ^a   Eilers, K M ^a   Wersinger, E M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Calcitriol; Chemotherapy; Docetaxel; Prostate cancer; Vitamin D

Indexed keywords

ANDROGEN; CALCITRIOL; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG INTERMITTENT THERAPY; DRUG SENSITIVITY; FATIGUE; HUMAN; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CALCITRIOL; DEXAMETHASONE; DISEASE-FREE SURVIVAL; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PACLITAXEL; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TAXOIDS;

EID: 0141956345     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601232     Document Type: Article

References (12)

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KC, Sullivan M, Takeda D (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376
2. Beer TM, Hough KM, Garzotto M, Lowe BA, Henner WD (2001) Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol 28: 49-55
3. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17: 3461-3467
4. Gilligan T, Kantoff PW (2002) Chemotherapy for prostate cancer. Urology 60: 94-100, discussion 100
5. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K (1995) Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45: 839-844, discussion 844-845
6. Higano CS, Ellis W, Russell K, Lange PH (1996) Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 48: 800-804
7. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17: 2506-2513
8. Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16: 139-144
9. Osoba D, Tannock IF, Ernst DS, Neville AJ (1999) Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 17: 1654-1663
10. Osoba D, Zee B, Pater J, Warr D, Kaizer L, Latreille J (1994) Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 3: 353-364
11. Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang NJ (2001) Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 19: 2509-2516
12. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756-1764